US · Healthcare · Medical Devices
EPS came in at -0.19 against a street estimate of -0.22 — a beat of 13.6%.
Analysts rate Alamar Biosciences, Inc. Common Stock a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $35.40.
| Fund | Stake |
|---|---|
| Sands Capital Ventures, LLC | 6.10% |
| Samsara BioCapital, LLC | 3.57% |
| T. Rowe Price Investment Management,Inc. | 3.17% |
| ARK Investment Management LLC | 1.98% |
| BRAIDWELL LP | 1.56% |
| AllianceBernstein L.P. | 1.45% |
| Hillhouse Capital Advisors, Ltd. | 1.38% |
| BlackRock Inc | 1.31% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $33,545,000, up from $19,913,000 in the third quarter of 2025. • Nine-month 2026 revenue was $89,0 | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $33.5 million, up 68% from $19.9 million in the third quarter of 2025. • Nine-month 2026 revenue w | 2026-11-03 |
| Board / officer change · Q3 2026 ALAMAR BIOSCIENCES, INC. - 8-K FILING SUMMARY HEADLINE NUMBERS • Company: Alamar Biosciences, Inc. (Ticker: ALMR, Nasdaq) • Filing Date: August 28, 2 | 2026-09-01 |
| Quarterly report · Q2 2026 ALAMAR BIOSCIENCES, INC. – 10-Q SUMMARY (Q2 2026) --- HEADLINE NUMBERS • Cash Position: $132.969 million in cash and cash equivalents as of June 30 | 2026-08-11 |
| Results announced · Q3 2026 ALAMAR BIOSCIENCES Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $29.4 million, up 82% year-over-year from $16.2 million in Q2 | 2026-08-10 |
| Company announcement · Q3 2026 ALAMAR BIOSCIENCES, INC. (ALMR) - 8-K SUMMARY OTHER NOTABLE POINTS • Ian Ratcliffe, an independent board member since February 2024, passed away on | 2026-07-15 |
| Quarterly report · Q1 2026 ALAMAR BIOSCIENCES, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $26.0 million (Product: $21.3M | Service/Other: $4.7M) — up 99% | 2026-05-08 |
| Results announced · Q2 2026 ALAMAR BIOSCIENCES Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenue: $26.0 million in Q1 2026, up 99% year-over-year from $13.1 million in | 2026-05-08 |
Readable in the app.
| Announcement | Date |
|---|---|
| Full-year 2026 revenue guidance raised to $121 million-$123 million Alamar Biosciences reported strong third-quarter growth but widening losses. Revenue rose 68% year over year to $33.5 million. Instrument revenue increased 50% to $8.5 million, consumables r | 2026-11-03 |
| Full-year 2026 revenue guidance of $116-120 million provided Alamar Biosciences, a proteomics company, reported strong Q2 2026 results with $29.4 million in revenue, up 82% year-over-year. Key performance highlights include consumable revenue surging | 2026-08-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alamar Biosciences, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.